Schedule of components of loss before income taxes |
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2019
|
|
2018
|
Domestic
|
|
$
|
(7,523,695)
|
|
$
|
(11,242,646)
|
Foreign
|
|
|
522,395
|
|
|
517,268
|
Total Loss Before Income Taxes
|
|
$
|
(7,001,300)
|
|
$
|
(10,725,378)
|
|
Schedule of components of income tax expense |
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2019
|
|
2018
|
Deferred Taxes:
|
|
|
|
|
|
|
Federal
|
|
$
|
(4,182)
|
|
$
|
1,814
|
State
|
|
|
99,578
|
|
|
84,231
|
Total Deferred Taxes
|
|
$
|
95,396
|
|
$
|
86,045
|
Income Tax Expense
|
|
$
|
95,396
|
|
$
|
86,045
|
|
Schedule of deferred tax assets and liabilities |
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2019
|
|
2018
|
Net Deferred Tax Liability:
|
|
|
|
|
|
|
Net Operating Loss Carryforwards
|
|
$
|
15,230,646
|
|
$
|
13,601,705
|
Research and Development Credit Carryforwards
|
|
|
2,594,055
|
|
|
2,124,949
|
Capitalized Research and Development
|
|
|
6,521,705
|
|
|
5,861,675
|
Stock-Based Compensation
|
|
|
814,438
|
|
|
639,729
|
Depreciation and Amortization
|
|
|
170
|
|
|
(3,217)
|
Cash Versus Accrual Adjustments
|
|
|
1,738,482
|
|
|
2,069,985
|
Total Deferred Tax Assets
|
|
|
26,899,496
|
|
|
24,294,826
|
Valuation Allowance
|
|
|
(26,278,147)
|
|
|
(23,659,844)
|
Net Deferred Tax Asset
|
|
|
621,349
|
|
|
634,982
|
In-Process Research and Development
|
|
|
(986,713)
|
|
|
(904,950)
|
Net Deferred Tax Liability
|
|
$
|
(365,364)
|
|
$
|
(269,968)
|
|